Virax Biolabs Group (VRAX) Projected to Post Earnings on Wednesday

Virax Biolabs Group (NASDAQ:VRAX) is expected to be posting its resultson Wednesday, June 3rd. Analysts expect Virax Biolabs Group to post earnings of ($0.07) per share and revenue of $0.0010 million for the quarter.

Virax Biolabs Group Stock Performance

Virax Biolabs Group stock opened at $0.23 on Wednesday. The business has a 50-day simple moving average of $0.17 and a two-hundred day simple moving average of $0.28. Virax Biolabs Group has a 52-week low of $0.10 and a 52-week high of $1.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $1.00.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.